

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Treatment options and barriers to case management of neonatal pneumonia in India: a systematic review (Protocol)

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-017617 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 03-May-2017 |
| Complete List of Authors: | Sreekumaran Nair, N; Manipal University, biostats Lewis, Leslie; Manipal University Kasturba Medical College Manipal, paediatrics Murthy, Shruti; Manipal University, Public Health Evidence South Asia (PHESA) Lakiang, Theophilus; Manipal University Godinho, Myron ; Manipal University, Public Health Evidence South Asia (PHESA) Venkatesh , Bhumika; Manipal University |
| Primary Subject Heading: | Infectious diseases |
| Secondary Subject Heading: | Infectious diseases |
| Keywords: | Neonate, Pneumonia, Treatment, Case management, Barriers, Systematic Review |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: A**
4 **Systematic Review (Protocol)**
5
6
7

8
9 N. Sreekumaran Nair¹, Leslie Edward Lewis², Shruti Murthy^{3*}, Myron Godinho^{3**},
10 Theophilus Lakiang^{3***}, Bhumika T. Venkatesh⁴
11
12

13
14
15 ¹ Director, Public Health Evidence South Asia (PHESA), & Professor of Biostatistics and Head,
16 Department of Statistics, Manipal University, Manipal. nskairmanipal@gmail.com

17 ² Professor and Head, Neonatology Unit, Department of Pediatrics, Kasturba Medical
18 College, Manipal University, Manipal. leslie.lewis@manipal.edu

19 ³ Research Associate, Public Health Evidence South Asia (PHESA), Manipal University,
20 Manipal;
21

22 *itzshruti@gmail.com

23 **myrongodinho@gmail.com

24 ***theo.lakiang@gmail.com

25
26
27 ⁴ Assistant Professor, Public Health Evidence South Asia (PHESA), Manipal University,
28 Manipal; meetbhumika123@gmail.com
29
30

31
32
33 **Correspondence to:**

34 Dr. N. Sreekumaran Nair

35 Director, Public Health Evidence South Asia (PHESA), Ground Floor, Manipal EDU Building,
36 and

37 Professor of Biostatistics and Head, Department of Statistics,

38 Level 6, Health Science Library Building,

39 Manipal University,

40 Manipal-576104, Karnataka, India

41 Email address: nskairmanipal@gmail.com

42 Telephone number: +91-8202922407
43
44

45 PROSPERO 2016:CRD42016045449
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: A**
4 **Systematic Review (Protocol)**
5
6
7

8 **Abstract**
9

10 **Introduction:** India contributes to the highest neonatal deaths globally. Case management is
11 said to be the cornerstone of pneumonia control. Much of the published evidence focuses
12 on children aged 1 to 59 months. This systematic review, thus, aims to identify the
13 treatment options for and barriers to case management of neonatal pneumonia in India.
14
15

16 **Methods and Analysis:** This protocol is part of a series of three systematic reviews on
17 neonatal pneumonia in India. Studies addressing treatment of or barriers to case
18 management of neonatal pneumonia in Indian context, published in English in peer-
19 reviewed and indexed journals will be eligible for inclusion. Electronic search will be
20 conducted on nine databases. Hand searching and snowballing will be done for published
21 and grey literature will be performed. Selection of studies will be done in title, abstract and
22 full text stages. A narrative summary will be performed to summarize the details of
23 evidence.
24
25
26
27
28
29
30
31
32

33 **Ethics and dissemination:** Since this is a review involving analysis of secondary data which is
34 available in the public domain, and does not involve human participants, ethical approval
35 was not required. The findings of the study will be shared with all stakeholders of this
36 research. Knowledge dissemination workshops will be conducted with relevant stakeholders
37 to ultimately transfer the evidence tailored to the stakeholder (e.g. policy briefs,
38 publications, information booklets, etc).
39
40
41
42
43
44

45 **Keywords:** Neonate, Pneumonia, Treatment, Case management, Barriers, Systematic
46 Review, India
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of the study

- Most documented literature in pneumonia case management address post-neonatal age groups. First review to consolidate research on the treatment modalities, their implementation, and the barriers to the case management of neonatal pneumonia in India.
- A comprehensive search strategy was developed over 9 databases including relevant regional databases and grey literature published in any year.
- The review will narratively summarize published literature. No quality assessment of included studies is planned.

Introduction

Globally, 5.9 million children died in 2015, out of which 2.6 million were neonates.¹ India accounts for more neonatal deaths than any other country.² More than half of the child deaths from pneumonia occur during the newborn period.³ In India, economic deprivation, impaired access to healthcare, harmful child-rearing practices, malnutrition and indoor air pollution are all major risk factors for pneumonia.⁴ Neonatal pneumonia is particularly difficult to define and classify, as witnessed by differing definitions in different studies.^{3 6}

In 2008, the World Health Organization (WHO)- United Nations Children's Fund (UNICEF) formulated the Global Action plan for the Prevention and control of Pneumonia (GAPP),⁷ and in India, the Integrated Management of Neonatal & Childhood Illness (IMNCI) is now an important part of the national strategy to control childhood illness. Timely detection, effective case management, and prompt referral can reduce child morbidity and mortality due to pneumonia.⁸ However, this is challenging in regions where co-morbid conditions (e.g. tuberculosis, malaria, AIDS) and antibiotic resistance prevail.⁶ These difficulties are compounded by the clinical overlap of neonatal sepsis and pneumonia,³ and obscured by conditions like hyaline membrane disease which mimic neonatal pneumonia, and impede detection in the absence of bacteriological confirmation.⁵ Moreover, injudicious antibiotic therapy could lead to resistance or treatment failure.⁹ A multitude of factors such as these pose special challenges to the initiation and maintenance of treatment, resulting in excessive morbidity and mortality.⁸ However, most documented difficulties in pneumonia

1
2
3 case management address post-neonatal age groups, and fail to discuss neonatal treatment
4 issues.
5

6
7 There is recognized need for consolidated research on the treatment modalities, their
8 implementation, and the barriers to the case management of neonatal pneumonia in India.
9 This evidence is required to inform the development of interventions, education and
10 preventive strategies to combat this scourge of India's newborn. Thus this systematic review
11 will attempt to synthesize evidence on different treatment options existing for neonatal
12 pneumonia and the factors hindering effective case management of neonatal pneumonia in
13 the Indian context.
14
15
16
17
18

19
20 The objectives of this systematic review are to identify the
21

- 22 1. Treatment options for neonatal pneumonia, and
- 23 2. Barriers to case management of neonatal pneumonia in the Indian context.
24
25
26

27 This protocol is part of a larger mixed-methods research project consisting of a qualitative
28 study and a trilogy of systematic reviews on neonatal pneumonia in India addressing risk
29 factors, management and predictors of mortality due to neonatal pneumonia in the Indian
30 context.
31
32
33
34
35

36 **Methods and analysis**

37 This review will be conducted from August 2016 to October 2017.
38
39

40 **Criteria for considering studies for this review**

41 Types of studies
42

43 *Inclusion criteria:* Studies eligible for inclusion should have been conducted among neonates
44 with pneumonia (or sepsis) in the Indian context, and their stakeholders. Eligible study
45 designs will include editorials, case reports, case series, cross sectional studies, case control
46 studies, cohort studies, intervention studies, qualitative studies, secondary data analysis,
47 policy papers, guidelines, reports, fact sheets addressing treatment of or barriers to case
48 management of neonatal pneumonia in Indian context. Studies have to be published in
49 English language in indexed and peer-reviewed journals to be eligible for inclusion.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Exclusion criteria:* The following studies will be excluded: all types of reviews, meta-analysis,
4 conference papers and reports which do not report on treatment or barriers to case
5 management of neonatal pneumonia in an Indian context.
6
7

8
9 Operational definitions: For the purpose of this review, treatment was operationally defined
10 as 'any specific or supportive treatment administered to a neonate with pneumonia'; case
11 management was defined as 'detection, investigation, treatment, referral, monitoring,
12 support or follow up of pneumonia in a neonate either in the facility or community'⁸; and
13 barrier to case management was defined as 'any difficulty or obstacle during the case
14 management of neonatal pneumonia'. Though we defined these terms in the beginning, our
15 intention will also be to capture the definitions, where available, as reported by the authors
16 and present them in the narrative synthesis.
17
18
19
20
21
22

23
24 Type of participants: Neonates with pneumonia in Indian context.
25

26 Outcomes of this review: Outcomes of this review will be (a) specific and supportive
27 treatment of- and (b) barriers to case management of neonatal pneumonia in Indian
28 context.
29
30
31

32 33 **Search methods for identification of studies:**

34
35 A comprehensive and relevant search strategy to identify all relevant studies will be
36 developed by reviewing literature and discussion with subject experts and an information
37 scientist. The search terms used and search strategies for PubMed have been provided in
38 Tables 1 and 2.
39
40

41
42 Electronic searches: We will search PubMed, Ovid Medline, ProQuest, EMBASE, CINAHL,
43 Web of Science, SCOPUS, WHOLIS and IndMED.
44

45 Hand searching: Hand searching will be conducted for reports/ guidelines/ journal volumes
46 not included in electronic databases and conference proceedings to review the references
47 and contact the authors for full text of identified literature.
48
49

50 Searching the grey literature: Potential sources of grey literature will include Shodhganga
51 (INFLIBNET) and Government of India databases for reports, fact sheets and guidelines/
52 policies in the Indian context.
53
54
55
56
57
58
59
60

Reference lists: Snowballing will be conducted to screen the references of identified literature for potentially relevant studies.

Table 1: Search strategy for treatment options (PubMed):

| Strategy: #1 AND #2 AND #3 | |
|----------------------------|---|
| #1 | ((((Neonate* OR childhood OR neonatal* OR newborn* OR "young infant" OR child OR pediatric* OR "neonatal period" OR infant* OR "newborn infant")))) |
| #2 | ((((((((((((((((((((((((((((((Pneumonia*) OR Pneumon*) OR "community acquired pneumonia") OR "congenital pneumonia") OR "hospital acquired pneumonia") OR "nosocomial pneumonia") OR "ventilator associated pneumonia") OR "early onset pneumonia") OR "late onset pneumonia") OR "infective pneumonia") OR "infectious pneumonia") OR "meconium aspiration syndrome") OR "meconium aspiration") OR "lipoid pneumonia") OR sepsis*) OR "acute respiratory infections") OR "early onset sepsis") OR "chemical pneumonia") OR "aspiration pneumonia") OR "late onset sepsis") OR infection*) OR "nosocomial infection") OR "early onset infection") OR "late onset infection") OR "acute lower respiratory infection") OR "hospital acquired infection") OR "congenital infection") OR "viral pneumonia") OR "gastro esophageal reflux disease") OR "cystic fibrosis")))) |
| #3 | ((((Treatment* OR Therap* OR "Patient care management" OR "Case management programs" OR "Home based neonatal care" OR "Case Management" OR "Clinical case management" OR "Community case management" OR "Integrated community case management" OR "Home based newborn care" OR "Case management models" OR Antibiotic* OR Ventilation* OR "Intensive care units" OR "Intensive care" OR "Neonatal intensive care units" OR "Special Newborn Care Units" OR "Injectable antibiotic" OR "oral antibiotic" OR "supportive therapy" OR "specific therapy" OR "specific treatment" OR "Supportive treatment")))) |
| Geographical filter: India | |
| Language Filter: English | |

Table 2: Search strategy for barriers to case management (PubMed)

| Strategy: #1 AND #2 AND #3 AND #4 | |
|-----------------------------------|---|
| #1 | ((((Neonate* OR childhood OR neonatal* OR newborn* OR "young infant" OR child OR pediatric* OR "neonatal period" OR infant* OR "newborn infant")))) |
| #2 | ((((((((((((((((((((((((((((((Pneumonia*) OR Pneumon*) OR "community acquired pneumonia") OR "congenital pneumonia") OR "hospital acquired pneumonia") OR "nosocomial pneumonia") OR "ventilator associated pneumonia") OR "early onset pneumonia") OR "late onset pneumonia") OR "infective pneumonia") OR "infectious pneumonia") OR "meconium aspiration syndrome") OR "meconium aspiration") OR "lipoid pneumonia") OR sepsis*) OR "acute respiratory infections") OR "early onset sepsis") OR "chemical pneumonia") OR "aspiration pneumonia") OR "late onset sepsis") OR infection*) OR "nosocomial infection") OR "early onset infection") OR "late onset infection") OR "acute lower respiratory infection") OR "hospital acquired infection") OR |

| | |
|----------------------------|---|
| | "congenital infection") OR "viral pneumonia") OR "gastro esophageal reflux disease") OR "cystic fibrosis") |
| #3 | ((Treatment* OR Therap* OR "Patient care management" OR "Case management programs" OR "Home based neonatal care" OR "Case Management" OR "Clinical case management" OR "Community case management" OR "Integrated community case management" OR "Home based newborn care" OR "Case management models" OR Antibiotic* OR Ventilation* OR "Intensive care units" OR "Intensive care" OR "Neonatal intensive care units" OR "Special Newborn Care Units" OR "Injectable antibiotic" OR "oral antibiotic" OR "supportive therapy" OR "specific therapy" OR "specific treatment" OR "Supportive treatment")) |
| #4 | ((Barriers* OR challenging OR challenge* OR obstacle* OR difficult* OR drawback OR problem* OR hurdle* OR hindrance* OR hinder* OR gap*)))) |
| Geographical filter: India | |
| Language filter: English | |

Data collection and management

The results (titles and/or abstracts) of the search will be managed using Endnote (v. x7). Study selection will be performed on Endnote (v. x7). Data will be extracted on Microsoft Excel 2007.

Selection of studies

Studies will be reviewed based on the exclusion and inclusion criteria by two authors (SM and TL) independently in three stages. Stage one or title screening will include assessment of each title for inclusion in the systematic review. If both authors reject a title, it will not be included in the review. Studies which are approved by either author will move to the second stage of appraisal. In the second or abstract screening stage will involve screening of abstracts of the titles selected in stage one for inclusion in the review. If both authors reject an abstract at this stage, it will not be included in the review. Studies which are approved by either author will move to the third and final stage of appraisal. Stage three, the full text screening stage, will comprise of screening the full text of the abstracts selected in stage two. Only those studies approved by both the authors at this stage will be included in the review. In the event of a study accepted by one author and rejected by another, a third author (MG) and a senior reviewer (SN or LL) will arbitrate and a consensus will be reached on whether to include the study or not.

Data extraction

1
2
3 The data extraction form was developed, using Microsoft Excel 2007, through an iterative
4 process involving discussions and pilot testing. After a round of discussion among the
5 authors, senior reviewers, subject and clinical experts, and statisticians, the form was pilot-
6 tested on one study of each type to ensure that it adequately facilitated the collection of
7 essential information required for the narrative synthesis. The key headings under which
8 data extraction will be done include (1) Study Characteristics (2) Methodological
9 characteristics (3) Treatment options and barriers to case management and (4) Other
10 important information.
11
12

13
14
15
16
17
18 A final list of articles will be prepared for data extraction. This standardised, pre-tested data
19 extraction form will be used independently by two authors (SM and TL) to extract data from
20 the selected studies. Disagreements will be resolved in the presence of third (MG) and
21 senior reviewer authors (SN and LL) by discussion and consensus. Any discrepancies
22 regarding inclusion of the study in the review will be discussed with the team and advisory
23 group, and a decision will be made regarding its inclusion in the review.
24
25
26
27
28

29 **Dealing with missing data**

30
31 In case of inadequacy, missing information, lack of clarity on information in methodology or
32 if outcomes are missing, authors of the respective studies will be contacted in an attempt to
33 obtain the required details. Despite this attempt, if the missing data retrieval on some
34 aspects of the outcome (like clarity, inadequacy) is not possible, the study will be included in
35 the narrative summary with a mention of the same.
36
37
38
39
40

41 **Data Synthesis**

42
43 A narrative summary will be performed to summarize the details of evidence. A discussion,
44 where applicable, on study limitations that should be considered when interpreting the
45 findings of the review will be included. The complete results of any analyses conducted,
46 including the final search strategy, will be reported. No quality assessment of the included
47 studies has been planned.
48
49
50
51
52

53
54 **Quality Control and Reporting of the systematic review:** A Preferred Reporting Items for
55 Systematic reviews and Meta-analysis (PRISMA) chart will be created, to outline and
56
57
58
59
60

1
2
3 summarise this study selection process.¹⁰The findings of this systematic review will be
4 reported in accordance with the PRISMA Guidelines.^{10 11}
5
6
7

8 **Ethics and dissemination:**

9
10
11 **Ethics:** Since this is a review involving analysis of secondary data which is available in the
12 public domain, and does not involve human participants, ethical approval was not required.
13

14
15 **Dissemination:** The findings of the study will be shared with all stakeholders of this
16 research. Knowledge dissemination workshops will be conducted with relevant stakeholders
17 to ultimately transfer the evidence tailored to the stakeholder (e.g. policy briefs,
18 publications, information booklets, etc).
19
20
21

22 **Acknowledgements**

23
24 We would like to thank the following individuals for their continuous support and guidance
25 during this process of protocol development: Dr. Manoj Das, Director Projects, The INCLEN
26 Trust International, New Delhi; Dr Anju Sinha, Deputy Director General, Scientist 'E', Division
27 of Child Health, Indian Council of Medical Research, New Delhi; Dr. K.K. Diwakar, Professor
28 and Head, Department of Neonatology, Associate Dean, Malankara Orthodox Syrian Church
29 Medical College, Kerala; Mrs. Ratheebhai V., Senior Librarian and Information Scientist, at
30 Manipal School at Communication, Manipal University, Manipal; Dr. Ravinder M. Pandey,
31 Professor and Head, Department of Biostatistics, All India Institute of Medical Sciences, New
32 Delhi; Dr. B. Shantharam Baliga, Professor, Department of Paediatrics, Kasturba medical
33 college, Mangalore, Karnataka, ; Dr. Shirish Darak, Senior researcher, PRAYAS, Pune,
34 Maharashtra; Dr. Unnikrishnan B., Associate Dean and Professor, Department of Community
35 Medicine, Kasturba Medical College, Mangalore. We also thank Public Health Evidence
36 South Asia (PHESA) and Manipal University, Manipal for providing the necessary institutional
37 and infrastructural support for the project. We would also like to thank The INCLEN Trust
38 International, New Delhi, and The Bill and Melinda Gates Foundation for the financial
39 support which made this project possible.
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **Contributorship statement**

54
55 SN is the guarantor of the review. SN, BV AND LL conceived the research idea and reviewed
56 the manuscript. SN and LL provided overall technical guidance. In addition, LL assisted in
57
58
59
60

1
2
3 developing search terms. SM, TL and MG designed the protocol, drafted the manuscript and
4 developed and pilot tested the search strategies and data extraction form.
5
6

7 **Funding:** This project is supported by a grant from Bill and Melinda Gates Foundation (grant
8 OPP1084307) to The INCLEN Trust International and sub-grant to Manipal University
9 (subgrant INC2015GNT004). The views expressed through this project do not necessarily
10 represent the views of Bill and Melinda Gates Foundation or The INCLEN Trust International
11 or Manipal University.
12
13

14 **Data sharing statement:** All data supporting this study will be provided as supplementary
15 material together with the manuscript of the study's final results.
16
17

18 **Competing Interests:** All authors have completed the ICMJE uniform disclosure form at
19 www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support (grants)
20 from Bill and Melinda Gates Foundation (grant OPP1084307) to The INCLEN Trust
21 International and sub-grant to Manipal University (subgrant INC2015GNT004), during the
22 conduct of the study and for the submitted work; no financial relationships with any
23 organisations that might have an interest in the submitted work in the previous three years;
24 no other relationships or activities that could appear to have influenced the submitted
25 work.
26
27
28
29
30
31
32
33
34

35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

References

1. UNICEF. Committing to Child Survival: A Promise Renewed, Progress Report 2015. 2015. *New York, USA: UNICEF* September 2015
2. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. *Bulletin of the World Health Organization* 2008;86(5):408-16B.
3. Reiterer F. Neonatal pneumonia. *Neonatal Bacterial Infection InTech* 2013
4. Ghimire M, Bhattacharya S, Narain J. Pneumonia in South-East Asia Region: Public health perspective. *The Indian journal of medical research* 2012;135(4):459.
5. Duke T. Neonatal pneumonia in developing countries. *Archives of Disease in Childhood-Fetal and Neonatal Edition* 2005;90(3):F211-FF19.
6. UNICEF. Integrated Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea (GAPPD) 2013 [accessed 2016 20/1/2016]. Available from: <http://www.who.int/>
7. UNICEF, World Health Organization. Global action plan for prevention and control of pneumonia (GAPP). 2009
8. Graham SM, English M, Hazir T, et al. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. *Bulletin of the World Health Organization* 2008;86(5):349-55.
9. Engle WD, Jackson GL, Sendelbach DM, et al. Pneumonia in term neonates: laboratory studies and duration of antibiotic therapy. *Journal of Perinatology* 2003;23(5):372-77.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Annals of internal medicine* 2009;151(4):W-65-W-94.

11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine* 2009;151(4):264-69.

For peer review only

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

| Section and topic | Item No | Checklist item | Compliance |
|-----------------------------------|---------|---|---|
| ADMINISTRATIVE INFORMATION | | | |
| Title: | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | Pg 1& 2 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | Not applicable |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | Pg 1 |
| Authors: | | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | Pg 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | Pg 9 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | Not applicable |
| Support: | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | Pg 10 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | Pg 10 |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | Pg 10 |
| INTRODUCTION | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | Pg 3-4 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | Pg 4 Modified accordingly for review of non-interventional studies |
| METHODS | | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | Pg 4-5 Modified accordingly for |

| | | | |
|------------------------------------|-----|--|--------------------------------------|
| | | | review of non-interventional studies |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | Pg 5-6 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | Pg 6-7 |
| Study records: | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | Pg 7 |
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | Pg 7 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | Pg 8 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | Pg 8 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | Pg 8 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | Pg 8 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised | Pg 8 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ) | No quantitative synthesis planned |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | Pg 8 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) | NIL |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) | None planned |

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

BMJ Open

Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: a protocol for a scoping review

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-017617.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 21-Jun-2017 |
| Complete List of Authors: | Sreekumaran Nair, N; Manipal University, biostats Lewis, Leslie; Manipal University Kasturba Medical College Manipal, paediatrics Murthy, Shruti; Manipal University, Public Health Evidence South Asia (PHESA) Godinho, Myron ; Manipal University, Public Health Evidence South Asia (PHESA) Lakiang, Theophilus; Manipal University Venkatesh , Bhumika; Manipal University |
| Primary Subject Heading: | Infectious diseases |
| Secondary Subject Heading: | Infectious diseases, Paediatrics |
| Keywords: | Neonate, Pneumonia, Treatment, Case management, Barriers, scoping review |
| | |

SCHOLARONE™
Manuscripts

only

1
2
3 **Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: a**
4 **protocol for a scoping review**
5
6
7

8
9 N. Sreekumaran Nair¹, Leslie Edward Lewis², Shruti Murthy^{3*}, Myron Godinho^{3**},
10 Theophilus Lakiang^{3***}, Bhumika T. Venkatesh⁴
11
12

13
14
15 ¹ Director, Public Health Evidence South Asia (PHESA), & Professor of Biostatistics and Head,
16 Department of Statistics, Manipal University, Manipal. sree.nair@manipal.edu,
17 nskknairmanipal@gmail.com
18

19
20 ² Professor and Head, Neonatology Unit, Department of Pediatrics, Kasturba Medical
21 College, Manipal University, Manipal. leslie.lewis@manipal.edu
22

23
24 ³ Research Associate, Public Health Evidence South Asia (PHESA), Manipal University,
25 Manipal;
26

27 *itzshruti@gmail.com
28

29 **myrongodinho@gmail.com
30

31 ***theo.lakiang@gmail.com
32

33 ⁴ Assistant Professor, Public Health Evidence South Asia (PHESA), Manipal University,
34 Manipal; meetbhumika123@gmail.com
35
36

37 **Correspondence to:**

38 Dr. N. Sreekumaran Nair

39 Director, Public Health Evidence South Asia (PHESA), Ground Floor, Manipal EDU Building,
40 and
41

42 Professor of Biostatistics and Head, Department of Statistics,
43 Level 6, Health Science Library Building,
44 Manipal University,
45

46 Manipal-576104, Karnataka, India

47 Email address: sree.nair@manipal.edu, nskknairmanipal@gmail.com

48 Telephone number: +91-8202922407
49
50

51 PROSPERO 2016:CRD42016045449
52
53
54
55
56
57
58
59
60

1
2
3 **Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: a**
4 **protocol for a scoping review**
5

6 **Abstract**
7

8 **Introduction:** India contributes to the highest neonatal deaths globally. Case management is
9 said to be the cornerstone of pneumonia control. Much of the published evidence focuses
10 on children aged 1 to 59 months. This scoping review, thus, aims to identify the treatment
11 options for and barriers to case management of neonatal pneumonia in India.
12
13
14

15 **Methods and Analysis:** This protocol is part of a series of three reviews on neonatal
16 pneumonia in India. Studies addressing treatment of or barriers to case management of
17 neonatal pneumonia in Indian context, published in English in peer-reviewed and indexed
18 journals will be eligible for inclusion. Electronic search will be conducted on nine databases.
19 Hand searching and snowballing will be done for published and grey literature will be
20 performed. Selection of studies will be done in title, abstract and full text stages. A narrative
21 summary will be performed to summarize the details of evidence.
22
23
24
25
26
27
28

29 **Ethics and dissemination:** Since this is a review involving analysis of secondary data which is
30 available in the public domain, and does not involve human participants, ethical approval
31 was not required. The findings of the study will be shared with all stakeholders of this
32 research. Knowledge dissemination workshops will be conducted with relevant stakeholders
33 to ultimately transfer the evidence tailored to the stakeholder (e.g. policy briefs,
34 publications, information booklets, etc).
35
36
37
38
39

40 **Keywords:** Neonate, Pneumonia, Treatment, Case management, Barriers, Scoping Review,
41 India
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of the study

- Most documented literature in pneumonia case management address post-neonatal age groups. First review to consolidate research on the treatment modalities, their implementation, and the barriers to the case management of neonatal pneumonia in India.
- A comprehensive search strategy was developed over 9 databases including relevant regional databases and grey literature published in any year.
- The review will narratively summarize published literature. No quality assessment of included studies is planned.

Introduction

Globally, 5.9 million children died in 2015, out of which 2.6 million were neonates.¹ India accounts for more neonatal deaths than any other country.² More than half of the child deaths from pneumonia occur during the newborn period.³ In India, economic deprivation, impaired access to healthcare, harmful child-rearing practices, malnutrition and indoor air pollution are all major risk factors for pneumonia.^{4 5} Neonatal pneumonia is particularly difficult to define and classify, as witnessed by differing definitions in different studies.^{3 6}

In 2008, the World Health Organization (WHO)- United Nations Children's Fund (UNICEF) formulated the Global Action plan for the Prevention and control of Pneumonia (GAPP),⁷ and in India, the Integrated Management of Neonatal & Childhood Illness (IMNCI) is now an important part of the national strategy to control childhood illness. Timely detection, effective case management, and prompt referral can reduce child morbidity and mortality due to pneumonia.⁸ However, this is challenging in regions where co-morbid conditions (e.g. tuberculosis, malaria, AIDS) and antibiotic resistance prevail.⁶ These difficulties are compounded by the clinical overlap of neonatal sepsis and pneumonia,³ and obscured by conditions like hyaline membrane disease which mimic neonatal pneumonia, and impede detection in the absence of bacteriological confirmation.⁵ Moreover, injudicious antibiotic therapy could lead to resistance or treatment failure.⁹ A multitude of factors such as these pose special challenges to the initiation and maintenance of treatment, resulting in excessive morbidity and mortality.⁸ However, most documented difficulties in pneumonia

1
2
3 case management address post-neonatal age groups, and fail to discuss neonatal treatment
4 issues.
5

6
7 There is recognized need for consolidated research on the treatment modalities, their
8 implementation, and the barriers to the case management of neonatal pneumonia in India.
9 This evidence is required to inform the development of interventions, education and
10 preventive strategies to combat this scourge of India's newborn. Thus this scoping review
11 will attempt to synthesize evidence on different treatment options existing for neonatal
12 pneumonia and the factors hindering effective case management of neonatal pneumonia in
13 the Indian context.
14
15
16
17
18

19
20 The objectives of this scoping review are to identify the
21

- 22 1. Treatment options for neonatal pneumonia, and
- 23 2. Barriers to case management of neonatal pneumonia in the Indian context.
24
25
26

27 This protocol is part of a larger mixed-methods research project consisting of a qualitative
28 study and a trilogy of two systematic and one scoping reviews on neonatal pneumonia in
29 India addressing risk factors, management and predictors of mortality due to neonatal
30 pneumonia in the Indian context.
31
32
33
34
35

36 **Methods and analysis**

37 This review will be conducted from August 2016 to October 2017.
38
39

40 **Criteria for considering studies for this review**

41 Types of studies
42

43 *Inclusion criteria:* Studies eligible for inclusion should have been conducted among neonates
44 with pneumonia (or sepsis) in the Indian context, and their stakeholders. Primary studies,
45 (of any study design including editorials, case reports, case series, cross-sectional studies,
46 case control studies, cohort studies, intervention studies and qualitative studies), policy
47 papers, guidelines, reports, and fact sheets, addressing treatment of or barriers to case
48 management of neonatal pneumonia in Indian context were eligible to be included in the
49 review. Studies have to be published in English language in indexed and peer-reviewed
50 journals to be eligible for inclusion.
51
52
53
54
55
56
57
58
59
60

1
2
3 *Exclusion criteria:* The following studies will be excluded: all types of reviews, meta-analysis,
4 conference papers and reports which do not report on treatment or barriers to case
5 management of neonatal pneumonia in an Indian context.
6
7

8
9 Operational definitions: For the purpose of this review, treatment was operationally defined
10 as 'any specific or supportive treatment administered to a neonate with pneumonia'; case
11 management was defined as 'detection, investigation, treatment, referral, monitoring,
12 support or follow up of pneumonia in a neonate either in the facility or community'⁸; and
13 barrier to case management was defined as 'any difficulty or obstacle during the case
14 management of neonatal pneumonia'. Though we defined these terms in the beginning, our
15 intention will also be to capture the definitions, where available, as reported by the authors
16 and present them in the narrative synthesis.
17
18
19
20
21
22

23
24 Type of participants: Neonates with pneumonia in Indian context.
25

26 Outcomes of this review: Outcomes of this review will be (a) specific and supportive
27 treatment of- and (b) barriers to case management of neonatal pneumonia in Indian
28 context.
29
30
31

32 33 **Search methods for identification of studies:** 34

35 A comprehensive and relevant search strategy to identify all relevant studies will be
36 developed by reviewing literature and discussion with subject experts and an information
37 scientist. The search terms used and search strategies for PubMed have been provided in
38 Tables 1 and 2.
39
40

41 Electronic searches: We will search PubMed, Ovid Medline, ProQuest, EMBASE, CINAHL,
42 Web of Science, SCOPUS, WHOLIS and IndMED.
43

44 Hand searching: Hand searching will be conducted for reports/ guidelines/ journal volumes
45 not included in electronic databases and conference proceedings to review the references
46 and contact the authors for full text of identified literature.
47
48

49 Searching the grey literature: Potential sources of grey literature will include Shodhganga
50 (INFLIBNET) and Government of India databases for reports, fact sheets and guidelines/
51 policies in the Indian context.
52
53
54
55
56
57
58
59
60

Reference lists: Snowballing will be conducted to screen the references of identified literature for potentially relevant studies.

Table 1: Search strategy for treatment options (PubMed):

| Strategy: #1 AND #2 AND #3 | |
|----------------------------|--|
| #1 | ((Neonate* OR childhood OR neonatal* OR newborn* OR "young infant" OR child OR paediatric OR pediatric* OR "neonatal period" OR infant* OR "newborn infant")) |
| #2 | (((((Pneumonia*) OR Pneumon*) OR "community acquired pneumonia") OR "congenital pneumonia") OR "hospital acquired pneumonia") OR "nosocomial pneumonia") OR "ventilator associated pneumonia") OR "early onset pneumonia") OR "late onset pneumonia") OR "infective pneumonia") OR "infectious pneumonia") OR "meconium aspiration syndrome") OR "meconium aspiration") OR "lipoid pneumonia") OR sepsis*) OR "acute respiratory infections") OR "early onset sepsis") OR "chemical pneumonia") OR "aspiration pneumonia") OR "late onset sepsis") OR infection*) OR "nosocomial infection") OR "early onset infection") OR "late onset infection") OR "acute lower respiratory infection") OR "hospital acquired infection") OR "congenital infection") OR "viral pneumonia") OR "gastro esophageal reflux disease") OR "cystic fibrosis")) |
| #3 | ((Treatment* OR Therap* OR "Patient care management" OR "Case management programs" OR "Home based neonatal care" OR "Case Management" OR "Clinical case management" OR "Community case management" OR "Integrated community case management" OR "Home based newborn care" OR "Case management models" OR Antibiotic* OR Ventilation* OR "Intensive care units" OR "Intensive care" OR "Neonatal intensive care units" OR "Special Newborn Care Units" OR "Injectable antibiotic" OR "oral antibiotic" OR "supportive therapy" OR "specific therapy" OR "specific treatment" OR "Supportive treatment")))) |
| Geographical filter: India | |
| Language Filter: English | |

Table 2: Search strategy for barriers to case management (PubMed)

| Strategy: #1 AND #2 AND #3 AND #4 | |
|-----------------------------------|--|
| #1 | ((((Neonate* OR childhood OR neonatal* OR newborn* OR "young infant" OR child OR paediatric OR pediatric* OR "neonatal period" OR infant* OR "newborn infant")) |
| #2 | (((((Pneumonia*) OR Pneumon*) OR "community acquired pneumonia") OR "congenital pneumonia") OR "hospital acquired pneumonia") OR "nosocomial pneumonia") OR "ventilator associated pneumonia") OR "early onset pneumonia") OR "late onset pneumonia") OR "infective pneumonia") OR "infectious pneumonia") OR "meconium aspiration syndrome") OR "meconium aspiration") OR "lipoid pneumonia") OR sepsis*) OR "acute respiratory infections") OR "early onset sepsis") OR "chemical pneumonia") OR "aspiration pneumonia") OR "late onset sepsis") OR infection*) OR "nosocomial infection") OR "early onset infection") OR "late onset infection") OR "acute lower respiratory infection") OR "hospital acquired infection") OR |

| | |
|--|---|
| | "congenital infection") OR "viral pneumonia") OR "gastro esophageal reflux disease") OR "cystic fibrosis") |
| #3 | ((Treatment* OR Therap* OR "Patient care management" OR "Case management programs" OR "Home based neonatal care" OR "Case Management" OR "Clinical case management" OR "Community case management" OR "Integrated community case management" OR "Home based newborn care" OR "Case management models" OR Antibiotic* OR Ventilation* OR "Intensive care units" OR "Intensive care" OR "Neonatal intensive care units" OR "Special Newborn Care Units" OR "Injectable antibiotic" OR "oral antibiotic" OR "supportive therapy" OR "specific therapy" OR "specific treatment" OR "Supportive treatment")) |
| #4 | ((Barriers* OR challenging OR challenge* OR obstacle* OR difficult* OR drawback OR problem* OR hurdle* OR hindrance* OR hinder* OR gap* OR cost* OR utilization OR satisfaction)))))) |
| Geographical filter: India Language filter: English | |

Data collection and management

The results (titles and/or abstracts) of the search will be managed using Endnote (v. x7). Study selection will be performed on Endnote (v. x7). Data will be extracted on Microsoft Excel 2007.

Selection of studies

Studies will be reviewed based on the exclusion and inclusion criteria by two authors (SM and TL) independently in three stages. Stage one or title screening will include assessment of each title for inclusion in the review. If both authors reject a title, it will not be included in the review. Studies which are approved by either author will move to the second stage of appraisal. In the second or abstract screening stage will involve screening of abstracts of the titles selected in stage one for inclusion in the review. If both authors reject an abstract at this stage, it will not be included in the review. Studies which are approved by either author will move to the third and final stage of appraisal. Stage three, the full text screening stage, will comprise of screening the full text of the abstracts selected in stage two. Only those studies approved by both the authors at this stage will be included in the review. In the event of a study accepted by one author and rejected by another, a third author (MG) and a senior reviewer (SN or LL) will arbitrate and a consensus will be reached on whether to include the study or not.

Data extraction

The data extraction form was developed, using Microsoft Excel 2007, through an iterative process involving discussions and pilot testing. After a round of discussion among the authors, senior reviewers, subject and clinical experts, and statisticians, the form was pilot-tested on one study of each type to ensure that it adequately facilitated the collection of essential information required for the narrative synthesis. The key headings under which data extraction will be done include (1) Study Characteristics (2) Methodological characteristics (3) Treatment options and barriers to case management and (4) Other important information.

A final list of articles will be prepared for data extraction. This standardised, pre-tested data extraction form will be used independently by two authors (SM and TL) to extract data from the selected studies. Disagreements will be resolved in the presence of third (MG) and senior reviewer authors (SN and LL) by discussion and consensus. Any discrepancies regarding inclusion of the study in the review will be discussed with the team and advisory group, and a decision will be made regarding its inclusion in the review.

Dealing with missing data

In case of inadequacy, missing information, lack of clarity on information in methodology or if outcomes are missing, authors of the respective studies will be contacted in an attempt to obtain the required details. Despite this attempt, if the missing data retrieval on some aspects of the outcome (like clarity, inadequacy) is not possible, the study will be included in the narrative summary with a mention of the same.

Data Synthesis

A narrative summary will be performed to summarize the details of evidence. A discussion, where applicable, on study limitations that should be considered when interpreting the findings of the review will be included. The complete results of any analyses conducted, including the final search strategy, will be reported. No quality assessment of the included studies has been planned.

Reporting of the scoping review: A Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) chart will be created, to outline and summarise this study selection

1
2
3 process.¹⁰The findings of this review will be reported in accordance with the PRISMA
4 Guidelines.^{10 11}
5
6
7

8 **Ethics and dissemination:**

9
10
11 **Ethics:** Since this is a review involving analysis of secondary data which is available in the
12 public domain, and does not involve human participants, ethical approval was not required.
13

14
15 **Dissemination:** The findings of the study will be shared with all stakeholders of this
16 research. Knowledge dissemination workshops will be conducted with relevant stakeholders
17 to ultimately transfer the evidence tailored to the stakeholder (e.g. policy briefs,
18 publications, information booklets, etc).
19
20
21

22 **Acknowledgements**

23
24 We would like to thank the following individuals for their continuous support and guidance
25 during this process of protocol development: Dr. Manoj Das, Director Projects, The INCLIN
26 Trust International, New Delhi; Dr Anju Sinha, Deputy Director General, Scientist 'E', Division
27 of Child Health, Indian Council of Medical Research, New Delhi; Dr. K.K. Diwakar, Professor
28 and Head, Department of Neonatology, Associate Dean, Malankara Orthodox Syrian Church
29 Medical College, Kerala; Mrs. Ratheebhai V., Senior Librarian and Information Scientist, at
30 Manipal School at Communication, Manipal University, Manipal; Dr. Ravinder M. Pandey,
31 Professor and Head, Department of Biostatistics, All India Institute of Medical Sciences, New
32 Delhi; Dr. B. Shantharam Baliga, Professor, Department of Paediatrics, Kasturba medical
33 college, Mangalore, Karnataka, ; Dr. Shirish Darak, Senior researcher, PRAYAS, Pune,
34 Maharashtra; Dr. Unnikrishnan B., Associate Dean and Professor, Department of Community
35 Medicine, Kasturba Medical College, Mangalore. We also thank Public Health Evidence
36 South Asia (PHESA) and Manipal University, Manipal for providing the necessary institutional
37 and infrastructural support for the project. We would also like to thank The INCLIN Trust
38 International, New Delhi, and The Bill and Melinda Gates Foundation for the financial
39 support which made this project possible.
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **Contributorship statement**

54
55 SN is the guarantor of the review. SN, BV AND LL conceived the research idea and reviewed
56 the manuscript. SN and LL provided overall technical guidance. In addition, LL assisted in
57
58
59
60

1
2
3 developing search terms. SM, TL and MG designed the protocol, drafted the manuscript and
4 developed and pilot tested the search strategies and data extraction form.
5
6

7 **Funding:** This project is supported by a grant from Bill and Melinda Gates Foundation (grant
8 OPP1084307) to The INCLEN Trust International and sub-grant to Manipal University
9 (subgrant INC2015GNT004). The views expressed through this project do not necessarily
10 represent the views of Bill and Melinda Gates Foundation or The INCLEN Trust International
11 or Manipal University.
12
13

14 **Data sharing statement:** All data supporting this study will be provided as supplementary
15 material together with the manuscript of the study's final results.
16
17

18 **Competing Interests:** All authors have completed the ICMJE uniform disclosure form at
19 www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support (grants)
20 from Bill and Melinda Gates Foundation (grant OPP1084307) to The INCLEN Trust
21 International and sub-grant to Manipal University (subgrant INC2015GNT004), during the
22 conduct of the study and for the submitted work; no financial relationships with any
23 organisations that might have an interest in the submitted work in the previous three years;
24 no other relationships or activities that could appear to have influenced the submitted
25 work.
26
27
28
29
30
31
32
33
34
35

36 References

- 37 1. UNICEF. Committing to Child Survival: A Promise Renewed, Progress Report 2015. 2015. *New York, USA: UNICEF* September 2015
- 38 2. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia.
39 *Bulletin of the World Health Organization* 2008;86(5):408-16B.
- 40 3. Reiterer F. Neonatal pneumonia. *Neonatal Bacterial Infection InTech* 2013
- 41 4. Ghimire M, Bhattacharya S, Narain J. Pneumonia in South-East Asia Region: Public health
42 perspective. *The Indian journal of medical research* 2012;135(4):459.
- 43 5. Duke T. Neonatal pneumonia in developing countries. *Archives of Disease in Childhood-Fetal and*
44 *Neonatal Edition* 2005;90(3):F211-FF19.
- 45 6. UNICEF. Integrated Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea
46 (GAPPD) 2013 [accessed 2016 20/1/2016]. Available from: <http://www.who.int/>
- 47 7. UNICEF, World Health Organization. Global action plan for prevention and control of pneumonia
48 (GAPP). 2009
- 49 8. Graham SM, English M, Hazir T, et al. Challenges to improving case management of childhood
50 pneumonia at health facilities in resource-limited settings. *Bulletin of the World Health*
51 *Organization* 2008;86(5):349-55.
- 52 9. Engle WD, Jackson GL, Sendelbach DM, et al. Pneumonia in term neonates: laboratory studies and
53 duration of antibiotic therapy. *Journal of Perinatology* 2003;23(5):372-77.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Annals of internal medicine* 2009;151(4):W-65-W-94.

11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine* 2009;151(4):264-69.

For peer review only

BMJ Open

Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: a protocol for a scoping review

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-017617.R2 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 14-Jul-2017 |
| Complete List of Authors: | Sreekumaran Nair, N; Manipal University, biostats Lewis, Leslie; Manipal University Kasturba Medical College Manipal, paediatrics Murthy, Shruti; Manipal University, Public Health Evidence South Asia (PHESA) Godinho, Myron ; Manipal University, Public Health Evidence South Asia (PHESA) Lakiang, Theophilus; Manipal University Venkatesh , Bhumika; Manipal University |
| Primary Subject Heading: | Infectious diseases |
| Secondary Subject Heading: | Infectious diseases, Paediatrics |
| Keywords: | Neonate, Pneumonia, Treatment, Case management, Barriers, scoping review |
| | |

SCHOLARONE™
Manuscripts

only

Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: a protocol for a scoping review

N. Sreekumaran Nair¹, Leslie Edward Lewis², Shruti Murthy^{3*}, Myron Godinho^{3**}, Theophilus Lakiang^{3***}, Bhumika T. Venkatesh⁴

¹ Director, Public Health Evidence South Asia (PHESA), & Professor of Biostatistics and Head, Department of Statistics, Manipal University, Manipal. sree.nair@manipal.edu, nskknairmanipal@gmail.com

² Professor and Head, Neonatology Unit, Department of Pediatrics, Kasturba Medical College, Manipal University, Manipal. leslie.lewis@manipal.edu

³ Research Associate, Public Health Evidence South Asia (PHESA), Manipal University, Manipal;

*itzshruti@gmail.com

**myrongodinho@gmail.com

***theo.lakiang@gmail.com

⁴ Assistant Professor, Public Health Evidence South Asia (PHESA), Manipal University, Manipal; meetbhumika123@gmail.com

Correspondence to:

Dr. N. Sreekumaran Nair

Director, Public Health Evidence South Asia (PHESA), Ground Floor, Manipal EDU Building, and

Professor of Biostatistics and Head, Department of Statistics, Level 6, Health Science Library Building, Manipal University,

Manipal-576104, Karnataka, India

Email address: sree.nair@manipal.edu, nskknairmanipal@gmail.com

Telephone number: +91-8202922407

PROSPERO 2016:CRD42016045449

1
2
3 **Treatment options and Barriers to Case Management of Neonatal Pneumonia in India: a**
4 **protocol for a scoping review**
5

6 **Abstract**
7

8 **Introduction:** India contributes to the highest neonatal deaths globally. Case management is
9 said to be the cornerstone of pneumonia control. Much of the published evidence focuses
10 on children aged 1 to 59 months. This scoping review, thus, aims to identify the treatment
11 options for and barriers to case management of neonatal pneumonia in India.
12
13
14

15 **Methods and Analysis:** This protocol is part of a series of three reviews on neonatal
16 pneumonia in India. Studies addressing treatment of or barriers to case management of
17 neonatal pneumonia in Indian context, published in English in peer-reviewed and indexed
18 journals will be eligible for inclusion. Electronic search will be conducted on nine databases.
19 Hand searching and snowballing will be done for published and grey literature will be
20 performed. Selection of studies will be done in title, abstract and full text stages. A narrative
21 summary will be performed to summarize the details of evidence.
22
23
24
25
26
27
28

29 **Ethics and dissemination:** Since this is a review involving analysis of secondary data which is
30 available in the public domain, and does not involve human participants, ethical approval
31 was not required. The findings of the study will be shared with all stakeholders of this
32 research. Knowledge dissemination workshops will be conducted with relevant stakeholders
33 to ultimately transfer the evidence tailored to the stakeholder (e.g. policy briefs,
34 publications, information booklets, etc).
35
36
37
38
39

40 **Keywords:** Neonate, Pneumonia, Treatment, Case management, Barriers, Scoping Review,
41 India
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of the study

- Most documented literature in pneumonia case management address post-neonatal age groups. First review to consolidate research on the treatment modalities, their implementation, and the barriers to the case management of neonatal pneumonia in India.
- A comprehensive search strategy was developed over 9 databases including relevant regional databases and grey literature published in any year.
- The review will narratively summarize published literature. No quality assessment of included studies is planned.

Introduction

Globally, 5.9 million children died in 2015, out of which 2.6 million were neonates.¹ India accounts for more neonatal deaths than any other country.² More than half of the child deaths from pneumonia occur during the newborn period.³ In India, economic deprivation, impaired access to healthcare, harmful child-rearing practices, malnutrition and indoor air pollution are all major risk factors for pneumonia.^{4 5} Neonatal pneumonia is particularly difficult to define and classify, as witnessed by differing definitions in different studies.^{3 6}

In 2008, the World Health Organization (WHO)- United Nations Children's Fund (UNICEF) formulated the Global Action plan for the Prevention and control of Pneumonia (GAPP),⁷ and in India, the Integrated Management of Neonatal & Childhood Illness (IMNCI) is now an important part of the national strategy to control childhood illness. Timely detection, effective case management, and prompt referral can reduce child morbidity and mortality due to pneumonia.⁸ However, this is challenging in regions where co-morbid conditions (e.g. tuberculosis, malaria, AIDS) and antibiotic resistance prevail.⁶ These difficulties are compounded by the clinical overlap of neonatal sepsis and pneumonia,³ and obscured by conditions like hyaline membrane disease which mimic neonatal pneumonia, and impede detection in the absence of bacteriological confirmation.⁵ Moreover, injudicious antibiotic therapy could lead to resistance or treatment failure.⁹ A multitude of factors such as these pose special challenges to the initiation and maintenance of treatment, resulting in excessive morbidity and mortality.⁸ However, most documented difficulties in pneumonia

1
2
3 case management address post-neonatal age groups, and fail to discuss neonatal treatment
4 issues.
5
6

7 There is recognized need for consolidated research on the treatment modalities, their
8 implementation, and the barriers to the case management of neonatal pneumonia in India.
9 This evidence is required to inform the development of interventions, education and
10 preventive strategies to combat this scourge of India's newborn. Thus this scoping review
11 will attempt to synthesize evidence on different treatment options existing for neonatal
12 pneumonia and the factors hindering effective case management of neonatal pneumonia in
13 the Indian context.
14
15
16
17
18
19

20 The objectives of this scoping review are to identify the
21

- 22 1. Treatment options for neonatal pneumonia, and
- 23 2. Barriers to case management of neonatal pneumonia in the Indian context.
24
25
26

27 This protocol is part of a larger mixed-methods research project consisting of a qualitative
28 study and a trilogy of two systematic and one scoping reviews on neonatal pneumonia in
29 India addressing risk factors, management and predictors of mortality due to neonatal
30 pneumonia in the Indian context.
31
32
33
34
35

36 **Methods and analysis**

37 This review will be conducted from August 2016 to October 2017.
38
39

40 **Criteria for considering studies for this review**

41 Types of studies
42

43 *Inclusion criteria:* Studies eligible for inclusion should have been conducted among neonates
44 with pneumonia (or sepsis) in the Indian context, and their stakeholders. Primary studies,
45 (of any study design including editorials, case reports, case series, cross-sectional studies,
46 case control studies, cohort studies, intervention studies and qualitative studies), policy
47 papers, guidelines, reports, and fact sheets, addressing treatment of or barriers to case
48 management of neonatal pneumonia in Indian context were eligible to be included in the
49 review. Studies have to be published in English language in indexed and peer-reviewed
50 journals to be eligible for inclusion.
51
52
53
54
55
56
57
58
59
60

1
2
3 *Exclusion criteria:* The following studies will be excluded: all types of reviews, meta-analysis,
4 conference papers and reports which do not report on treatment or barriers to case
5 management of neonatal pneumonia in an Indian context.
6
7

8
9 Operational definitions: For the purpose of this review, treatment was operationally defined
10 as 'any specific or supportive treatment administered to a neonate with pneumonia'; case
11 management was defined as 'detection, investigation, treatment, referral, monitoring,
12 support or follow up of pneumonia in a neonate either in the facility or community'⁸; and
13 barrier to case management was defined as 'any difficulty or obstacle during the case
14 management of neonatal pneumonia'. Though we defined these terms in the beginning, our
15 intention will also be to capture the definitions, where available, as reported by the authors
16 and present them in the narrative synthesis.
17
18
19
20
21
22

23
24 Type of participants: Neonates with pneumonia in Indian context.
25

26 Outcomes of this review: Outcomes of this review will be (a) specific and supportive
27 treatment of- and (b) barriers to case management of neonatal pneumonia in Indian
28 context.
29
30
31

32 33 **Search methods for identification of studies:**

34
35 A comprehensive and relevant search strategy to identify all relevant studies will be
36 developed by reviewing literature and discussion with subject experts and an information
37 scientist. The search terms used and search strategies for PubMed have been provided in
38 Tables 1 and 2.
39
40

41
42 Electronic searches: We will search PubMed, Ovid Medline, ProQuest, EMBASE, CINAHL,
43 Web of Science, SCOPUS, WHOLIS and IndMED.
44

45 Hand searching: Hand searching will be conducted for reports/ guidelines/ journal volumes
46 not included in electronic databases and conference proceedings to review the references
47 and contact the authors for full text of identified literature.
48
49

50 Searching the grey literature: Potential sources of grey literature will include Shodhganga
51 (INFLIBNET) and Government of India databases for reports, fact sheets and guidelines/
52 policies in the Indian context.
53
54
55
56
57
58
59
60

Reference lists: Snowballing will be conducted to screen the references of identified literature for potentially relevant studies.

Table 1: Search strategy for treatment options (PubMed):

| Strategy: #1 AND #2 AND #3 | |
|----------------------------|--|
| #1 | ((Neonate* OR childhood OR neonatal* OR newborn* OR "young infant" OR child OR paediatric OR pediatric* OR "neonatal period" OR infant* OR "newborn infant")) |
| #2 | (((((Pneumonia*) OR Pneumon*) OR "community acquired pneumonia") OR "congenital pneumonia") OR "hospital acquired pneumonia") OR "nosocomial pneumonia") OR "ventilator associated pneumonia") OR "early onset pneumonia") OR "late onset pneumonia") OR "infective pneumonia") OR "infectious pneumonia") OR "meconium aspiration syndrome") OR "meconium aspiration") OR "lipoid pneumonia") OR sepsis*) OR "acute respiratory infections") OR "early onset sepsis") OR "chemical pneumonia") OR "aspiration pneumonia") OR "late onset sepsis") OR infection*) OR "nosocomial infection") OR "early onset infection") OR "late onset infection") OR "acute lower respiratory infection") OR "hospital acquired infection") OR "congenital infection") OR "viral pneumonia") OR "gastro esophageal reflux disease") OR "cystic fibrosis")) |
| #3 | ((Treatment* OR Therap* OR "Patient care management" OR "Case management programs" OR "Home based neonatal care" OR "Case Management" OR "Clinical case management" OR "Community case management" OR "Integrated community case management" OR "Home based newborn care" OR "Case management models" OR Antibiotic* OR Ventilation* OR "Intensive care units" OR "Intensive care" OR "Neonatal intensive care units" OR "Special Newborn Care Units" OR "Injectable antibiotic" OR "oral antibiotic" OR "supportive therapy" OR "specific therapy" OR "specific treatment" OR "Supportive treatment")) |
| Geographical filter: India | |
| Language Filter: English | |

Table 2: Search strategy for barriers to case management (PubMed)

| Strategy: #1 AND #2 AND #3 AND #4 | |
|-----------------------------------|--|
| #1 | ((((Neonate* OR childhood OR neonatal* OR newborn* OR "young infant" OR child OR paediatric OR pediatric* OR "neonatal period" OR infant* OR "newborn infant")) |
| #2 | (((((Pneumonia*) OR Pneumon*) OR "community acquired pneumonia") OR "congenital pneumonia") OR "hospital acquired pneumonia") OR "nosocomial pneumonia") OR "ventilator associated pneumonia") OR "early onset pneumonia") OR "late onset pneumonia") OR "infective pneumonia") OR "infectious pneumonia") OR "meconium aspiration syndrome") OR "meconium aspiration") OR "lipoid pneumonia") OR sepsis*) OR "acute respiratory infections") OR "early onset sepsis") OR "chemical pneumonia") OR "aspiration pneumonia") OR "late onset sepsis") OR infection*) OR "nosocomial infection") OR "early onset infection") OR "late onset infection") OR "acute lower respiratory infection") OR "hospital acquired infection") OR |

| | |
|--|---|
| | "congenital infection") OR "viral pneumonia") OR "gastro esophageal reflux disease") OR "cystic fibrosis") |
| #3 | ((Treatment* OR Therap* OR "Patient care management" OR "Case management programs" OR "Home based neonatal care" OR "Case Management" OR "Clinical case management" OR "Community case management" OR "Integrated community case management" OR "Home based newborn care" OR "Case management models" OR Antibiotic* OR Ventilation* OR "Intensive care units" OR "Intensive care" OR "Neonatal intensive care units" OR "Special Newborn Care Units" OR "Injectable antibiotic" OR "oral antibiotic" OR "supportive therapy" OR "specific therapy" OR "specific treatment" OR "Supportive treatment")) |
| #4 | ((Barriers* OR challenging OR challenge* OR obstacle* OR difficult* OR drawback OR problem* OR hurdle* OR hindrance* OR hinder* OR gap* OR cost* OR utilization OR satisfaction)))))) |
| Geographical filter: India Language filter: English | |

Data collection and management

The results (titles and/or abstracts) of the search will be managed using Endnote (v. x7). Study selection will be performed on Endnote (v. x7). Data will be extracted on Microsoft Excel 2007.

Selection of studies

Studies will be reviewed based on the exclusion and inclusion criteria by two authors (SM and TL) independently in three stages. Stage one or title screening will include assessment of each title for inclusion in the review. If both authors reject a title, it will not be included in the review. Studies which are approved by either author will move to the second stage of appraisal. In the second or abstract screening stage will involve screening of abstracts of the titles selected in stage one for inclusion in the review. If both authors reject an abstract at this stage, it will not be included in the review. Studies which are approved by either author will move to the third and final stage of appraisal. Stage three, the full text screening stage, will comprise of screening the full text of the abstracts selected in stage two. Only those studies approved by both the authors at this stage will be included in the review. In the event of a study accepted by one author and rejected by another, a third author (MG) and a senior reviewer (SN or LL) will arbitrate and a consensus will be reached on whether to include the study or not.

Data extraction and Charting the results

A charting form was developed, in Microsoft Excel 2007, through an iterative process involving discussions and pilot testing. After a round of discussion among the authors, senior reviewers, subject and clinical experts, and statisticians, the form was pilot-tested on one study of each type to ensure that it adequately facilitated the collection of essential information required for the narrative synthesis. The key headings under which charting will be done include (1) Study Characteristics (2) Methodological characteristics (3) Treatment options and barriers to case management and (4) Other important information.

This standardised, pre-tested charting form will be used independently by two authors (SM and TL) to extract data from the selected studies. Disagreements will be resolved in the presence of third (MG) and senior reviewer authors (SN and LL) by discussion and consensus. Any discrepancies regarding inclusion of the study in the review will be discussed with the team and advisory group, and a decision will be made regarding its inclusion in the review.

Dealing with missing data

In case of inadequacy, missing information, lack of clarity on information in methodology or if outcomes are missing, authors of the respective studies will be contacted in an attempt to obtain the required details. Despite this attempt, if the missing data retrieval on some aspects of the outcome (like clarity, inadequacy) is not possible, the study will be included in the narrative summary with a mention of the same.

Reporting the results

The complete results of any analyses conducted, including the final search strategy, will be reported. Results will be in tabular form supplemented with a descriptive summary of the findings. Tables will present the characteristics of included studies (study ID, year of publication, location and setting, study design and sample size, definitions adopted in the studies, treatments recommended by guidelines, treatments reported by primary research studies for neonatal pneumonia, and barriers reported during the case management of neonatal pneumonia. The descriptive summary will include details about the study objectives, the approach adopted and the findings. A discussion, where applicable, on study

1
2
3 limitations that should be considered when interpreting the findings of the review will be
4 included. No quality assessment of the included studies has been planned.

5
6 A Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) chart will
7 be created, to outline and summarise this study selection process.¹⁰The findings of this
8 review will be reported in accordance with the “Guidance for conducting systematic scoping
9 reviews”.¹¹

14 15 **Ethics and dissemination:**

16
17
18 **Ethics:** Since this is a review involving analysis of secondary data which is available in the
19 public domain, and does not involve human participants, ethical approval was not required.

20
21
22 **Dissemination:** The findings of the study will be shared with all stakeholders of this
23 research. Knowledge dissemination workshops will be conducted with relevant stakeholders
24 to ultimately transfer the evidence tailored to the stakeholder (e.g. policy briefs,
25 publications, information booklets, etc).

26 27 28 **Acknowledgements**

29
30
31 We would like to thank the following individuals for their continuous support and guidance
32 during this process of protocol development: Dr. Manoj Das, Director Projects, The INCLIN
33 Trust International, New Delhi; Dr Anju Sinha, Deputy Director General, Scientist ‘E’, Division
34 of Child Health, Indian Council of Medical Research, New Delhi; Dr. K.K. Diwakar, Professor
35 and Head, Department of Neonatology, Associate Dean, Malankara Orthodox Syrian Church
36 Medical College, Kerala; Mrs. Ratheebhai V., Senior Librarian and Information Scientist, at
37 Manipal School at Communication, Manipal University, Manipal; Dr. Ravinder M. Pandey,
38 Professor and Head, Department of Biostatistics, All India Institute of Medical Sciences, New
39 Delhi; Dr. B. Shantharam Baliga, Professor, Department of Paediatrics, Kasturba medical
40 college, Mangalore, Karnataka, ; Dr. Shirish Darak, Senior researcher, PRAYAS, Pune,
41 Maharashtra; Dr. Unnikrishnan B., Associate Dean and Professor, Department of Community
42 Medicine, Kasturba Medical College, Mangalore. We also thank Public Health Evidence
43 South Asia (PHESA) and Manipal University, Manipal for providing the necessary institutional
44 and infrastructural support for the project. We would also like to thank The INCLIN Trust
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 International, New Delhi, and The Bill and Melinda Gates Foundation for the financial
4 support which made this project possible.

7 **Contributorship statement**

8
9 SN is the guarantor of the review. SN, BV AND LL conceived the research idea and reviewed
10 the manuscript. SN and LL provided overall technical guidance. In addition, LL assisted in
11 developing search terms. SM, TL and MG designed the protocol, drafted the manuscript and
12 developed and pilot tested the search strategies and data extraction form.

13
14
15
16
17 **Funding:** This project is supported by a grant from Bill and Melinda Gates Foundation (grant
18 OPP1084307) to The INCLEN Trust International and sub-grant to Manipal University
19 (subgrant INC2015GNT004). The views expressed through this project do not necessarily
20 represent the views of Bill and Melinda Gates Foundation or The INCLEN Trust International
21 or Manipal University.

22
23
24
25
26
27 **Data sharing statement:** All data supporting this study will be provided as supplementary
28 material together with the manuscript of the study's final results.

29
30
31 **Competing Interests:** All authors have completed the ICMJE uniform disclosure form at
32 www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support (grants)
33 from Bill and Melinda Gates Foundation (grant OPP1084307) to The INCLEN Trust
34 International and sub-grant to Manipal University (subgrant INC2015GNT004)., during the
35 conduct of the study and for the submitted work; no financial relationships with any
36 organisations that might have an interest in the submitted work in the previous three years;
37 no other relationships or activities that could appear to have influenced the submitted
38 work.

39 **References**

- 40
41
42
43
44
45
46
47
48
49 1. UNICEF. Committing to Child Survival: A Promise Renewed, Progress Report 2015. 2015. *New York,*
50 *USA: UNICEF* September 2015
51 2. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia.
52 *Bulletin of the World Health Organization* 2008;86(5):408-16B.
53 3. Reiterer F. Neonatal pneumonia. *Neonatal Bacterial Infection InTech* 2013
54 4. Ghimire M, Bhattacharya S, Narain J. Pneumonia in South-East Asia Region: Public health
55 perspective. *The Indian journal of medical research* 2012;135(4):459.
56 5. Duke T. Neonatal pneumonia in developing countries. *Archives of Disease in Childhood-Fetal and*
57 *Neonatal Edition* 2005;90(3):F211-FF19.
58
59
60

- 1
- 2
- 3 6. UNICEF. Integrated Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea
- 4 (GAPPD) 2013 [cited 2016 20/1/2016]. Available from:
- 5 [http://www.who.int/maternal_child_adolescent/documents/global_action_plan_pneumonia](http://www.who.int/maternal_child_adolescent/documents/global_action_plan_pneumonia_diarrhoea/en)
- 6 [a_diarrhoea/en](http://www.who.int/maternal_child_adolescent/documents/global_action_plan_pneumonia_diarrhoea/en).
- 7
- 8 7. UNICEF, Organization WH. Global action plan for prevention and control of pneumonia (GAPP).
- 9 2009
- 10
- 11 8. Graham SM, English M, Hazir T, et al. Challenges to improving case management of childhood
- 12 pneumonia at health facilities in resource-limited settings. *Bulletin of the World Health*
- 13 *Organization* 2008;86(5):349-55.
- 14
- 15 9. Engle WD, Jackson GL, Sendelbach DM, et al. Pneumonia in term neonates: laboratory studies and
- 16 duration of antibiotic therapy. *Journal of Perinatology* 2003;23(5):372-77.
- 17
- 18 10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews
- 19 and meta-analyses of studies that evaluate health care interventions: explanation and
- 20 elaboration. *Annals of internal medicine* 2009;151(4):W-65-W-94.
- 21
- 22 11. Peters MD, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews.
- 23 *International journal of evidence-based healthcare* 2015;13(3):141-46.
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60